ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)
暂无分享,去创建一个
K. Do | W. Plunkett | M. Keating | Y. Jiang | W. Wierda | P. Thompson | H-C Chen | X. Su | X. Liu
[1] T. Stankovic,et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. , 2016, Blood.
[2] M. Grever,et al. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997 , 2015, Leukemia & lymphoma.
[3] Y. Shiloh. ATM: expanding roles as a chief guardian of genome stability. , 2014, Experimental cell research.
[4] T. Stankovic,et al. The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia , 2014, Leukemia & lymphoma.
[5] A. Shelat,et al. Development of a Cell-Based, High-Throughput Screening Assay for ATM Kinase Inhibitors , 2014, Journal of biomolecular screening.
[6] R. Yarden,et al. BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation , 2013, Oncogene.
[7] Gabor T. Marth,et al. MOSAIK: A Hash-Based Algorithm for Accurate Next-Generation Sequencing Short-Read Mapping , 2013, PloS one.
[8] Š. Pospíšilová,et al. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin , 2013, Haematologica.
[9] Roman K. Thomas,et al. Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors , 2013, Science Translational Medicine.
[10] A. Pettitt,et al. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia , 2013, Leukemia & lymphoma.
[11] Jun Yu,et al. MicroRNA-18a Attenuates DNA Damage Repair through Suppressing the Expression of Ataxia Telangiectasia Mutated in Colorectal Cancer , 2013, PloS one.
[12] M. Dyer,et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] P. Ouillette,et al. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia , 2012, Genes, chromosomes & cancer.
[14] J. Byrd,et al. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study , 2012, Leukemia & lymphoma.
[15] A. Dobrovic,et al. No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia , 2012, Leukemia & lymphoma.
[16] R. Foà,et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression , 2012, Haematologica.
[17] M. Dyer,et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele , 2012, Haematologica.
[18] Libing Song,et al. miR-18a Impairs DNA Damage Response through Downregulation of Ataxia Telangiectasia Mutated (ATM) Kinase , 2011, PloS one.
[19] M. Dyer,et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.
[20] R. Gatti,et al. ATM is down-regulated by N-Myc–regulated microRNA-421 , 2010, Proceedings of the National Academy of Sciences.
[21] Lisa S. Chen,et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.
[22] M. Dyer,et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL , 2008, Leukemia.
[23] R. Siebert,et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Yingli Sun,et al. DNA Damage-Induced Acetylation of Lysine 3016 of ATM Activates ATM Kinase Activity , 2007, Molecular and Cellular Biology.
[25] B. A. Ballif,et al. ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage , 2007, Science.
[26] Lingbao Ai,et al. Promoter hypermethylation of multiple genes in primary gastric lymphoma , 2007 .
[27] E. Appella,et al. Wip1 phosphatase modulates ATM-dependent signaling pathways. , 2006, Molecular cell.
[28] Y. Shiloh,et al. Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway , 2006, Nature Cell Biology.
[29] T. Stankovic,et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.
[30] Xiaofeng Jiang,et al. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] L. Hutchins,et al. Methylation Profiling of Archived Non–Small Cell Lung Cancer: A Promising Prognostic System , 2005, Clinical Cancer Research.
[32] D. Ginzinger,et al. The ATM gene is a target for epigenetic silencing in locally advanced breast cancer , 2004, Oncogene.
[33] K. Khanna,et al. Autophosphorylation of ataxia‐telangiectasia mutated is regulated by protein phosphatase 2A , 2004, The EMBO journal.
[34] Xiao-Fan Wang,et al. Requirement of protein phosphatase 5 in DNA-damage-induced ATM activation. , 2004, Genes & development.
[35] F. Gumy-Pause,et al. ATM gene and lymphoid malignancies , 2004, Leukemia.
[36] M. Kastan,et al. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.
[37] M. Kastan,et al. Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. , 2002, Genes & development.
[38] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[39] Gabor T. Marth,et al. A general approach to single-nucleotide polymorphism discovery , 1999, Nature Genetics.
[40] Yosef Shiloh,et al. Recombinant ATM protein complements the cellular A-T phenotype , 1997, Oncogene.
[41] Y. Shiloh,et al. Predominance of null mutations in ataxia-telangiectasia. , 1996, Human molecular genetics.
[42] A. Taylor,et al. Leukemia and lymphoma in ataxia telangiectasia. , 1996, Blood.
[43] Adrian E. Raftery,et al. mclust Version 4 for R : Normal Mixture Modeling for Model-Based Clustering , Classification , and Density Estimation , 2012 .
[44] M. Lowery-Nordberg,et al. Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia , 2009, Leukemia.
[45] Lingbao Ai,et al. Promoter hypermethylation of multiple genes in gastric lymphoma. , 2007, Leukemia & lymphoma.
[46] K. Brown,et al. Short Communication Ataxia-Telangiectasia-Mutated (ATM) Gene in Head and Neck Squamous Cell Carcinoma: Promoter Hypermethylation with Clinical Correlation in 100 Cases , 2004 .